Does high-dose vitamin C fight cancer?
Weak EvidenceNO
Weak evidence supports high-dose vitamin C as a cancer treatment. Intravenous (IV) vitamin C shows some anticancer activity in preclinical models and early-phase trials, but large RCTs of oral vitamin C found no survival benefit. IV vitamin C may improve quality of life in advanced cancer but is not a proven anti-tumor therapy.
The Verdict
Weak evidence supports high-dose vitamin C as a cancer treatment. Intravenous (IV) vitamin C shows some anticancer activity in preclinical models and early-phase trials, but large RCTs of oral vitamin C found no survival benefit. IV vitamin C may improve quality of life in advanced cancer but is not a proven anti-tumor therapy.
What the Evidence Shows
The vitamin C and cancer story has been contentious since Linus Pauling's claims in the 1970s. The critical distinction is route of administration: oral vitamin C achieves maximum plasma levels of ~200 μmol/L regardless of dose due to intestinal absorption limits, while IV administration can achieve 10-20 mmol/L—concentrations shown to be selectively cytotoxic to cancer cells in vitro through pro-oxidant hydrogen peroxide generation. Two Mayo Clinic RCTs in the 1980s using oral vitamin C (10g/day) found no cancer survival benefit, effectively ending mainstream interest for decades. However, renewed research since 2005 focuses on IV administration. Phase I/II trials demonstrate that IV vitamin C (1-1.5g/kg, 2-3x weekly) is safe alongside chemotherapy, may reduce chemotherapy side effects, and shows modest tumor response signals in pancreatic, ovarian, and colorectal cancers. However, no Phase III RCT has demonstrated a survival benefit. The mechanism—generating tumor-selective oxidative stress via hydrogen peroxide—is plausible but dose-dependent and may only work in cancers with specific metabolic vulnerabilities (low catalase expression). Quality-of-life improvements and reduced fatigue are the most consistently reported patient benefits. Major cancer organizations do not recommend vitamin C as a cancer treatment but acknowledge the ongoing research for IV formulations.
Evidence Quality
2
Meta-Analyses
6
RCTs
8
Observational
Important Caveats
- ⚠️ Oral vitamin C cannot achieve cytotoxic plasma concentrations—only IV is relevant for cancer
- ⚠️ No Phase III RCT has shown survival benefit in any cancer type
- ⚠️ Earlier negative trials used oral dosing, which is pharmacokinetically irrelevant to the IV hypothesis
- ⚠️ Possible interference with certain chemotherapy agents (bortezomib, radiation) is debated
- ⚠️ Quality of life benefits do not equal anti-tumor efficacy
Population Studied
Advanced cancer patients (primarily pancreatic, ovarian, colorectal, lung) undergoing or refractory to standard treatment; Phase I/II trials with 20-60 participants
Dosage
IV doses: 1-1.5g/kg body weight (typically 50-100g per infusion), 2-3 times per week; oral supplementation studies used 1-10g/day (now considered inadequate for anticancer effect)
Duration
IV protocols typically administered for 8-24 weeks alongside chemotherapy cycles; acute cytotoxic effects require sustained high plasma levels for hours
Supporting Studies (3)
High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy
RCTMa Y, Chapman J, Levine M, et al. · Science Translational Medicine (2014)
Phase I/II trial in ovarian cancer patients found IV vitamin C (75-100g, 2x/week) combined with chemotherapy reduced chemotherapy-associated toxicity and showed a trend toward improved time to relapse compared to chemotherapy alone.
View paper (DOI) →Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice
RCTChen Q, Espey MG, Sun AY, et al. · Proceedings of the National Academy of Sciences (2008)
IV ascorbate achieving pharmacologic concentrations (>1 mM) generated hydrogen peroxide selectively in tumor tissue, reducing tumor growth by 41-53% in mouse xenograft models without affecting normal tissues.
View paper (DOI) →Intravenous vitamin C in cancer patients: a systematic review of quality of life outcomes
Systematic ReviewCarr AC, Vissers MCM, Cook JS. · Nutrients (2014)
Review of 12 clinical studies found IV vitamin C consistently improved quality of life, reduced fatigue, and decreased pain in advanced cancer patients, though anti-tumor effects were not consistently demonstrated.
View paper (DOI) →Contradicting Studies (2)
Failure of high-dose vitamin C therapy to benefit patients with advanced cancer: a controlled trial
RCTMoertel CG, Fleming TR, Creagan ET, et al. · New England Journal of Medicine (1985)
A double-blind RCT of 100 advanced colorectal cancer patients found oral vitamin C (10g/day) provided no survival advantage over placebo, with median survival identical between groups.
Why this disagrees:
The definitive Mayo Clinic trial found no cancer benefit, though modern proponents argue oral dosing cannot achieve pharmacologic plasma concentrations and the study is therefore not relevant to IV vitamin C claims.
Vitamin C supplements and cancer incidence and mortality: a meta-analysis of prospective cohort studies
Meta-AnalysisHua X, Li M, Pan F, et al. · BMC Cancer (2019)
Meta-analysis of 18 prospective studies involving over 800,000 participants found no significant association between vitamin C intake (dietary or supplemental) and overall cancer mortality.
Why this disagrees:
Large-scale population evidence does not support vitamin C intake—whether from diet or supplements—as protective against cancer mortality, undermining the broader narrative of vitamin C as an anticancer agent.